Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Dr Richard Goodfellow Chief Executive Officer ADDRESS Scancell Ltd Dept Clinical Oncology City Hospital Hucknall Road Nottingham NG5 1PB EMAIL richardgoodfellow@scancell.co.uk Scancell www.scancell.co.uk COMPANY PROFILE Scancell is developing novel therapeutic vaccines for the treatment of cancer and based on its groundbreaking ImmunoBody® and Moditope technology platforms. Scancell’s first cancer vaccine SCIB1 is a DNA vaccine being developed for the treatment of melanoma and is in Phase 2 clinical trials. Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations. The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope platform could have a profound effect on the way that cancer vaccines are developed. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Dr Hans Fliri Chairman Simon Bury Business Development Director – Discovery ADDRESS Selcia Limited Fyfield Business & Research Park, Fyfield Road, Ongar, Essex CM5 0GS UK TELEPHONE +44 1277 367000 FAX +44 1277 367099 EMAIL simon.bury@selcia.com contact@selcia.com YEAR FOUNDED 2001 Selcia Limited www.selcia.com COMPANY PROFILE Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, operates two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products, (2) capillary electrophoresis -based fragment and natural product screening, (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products. The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies. MANAGEMENT Simon Saxby, CEO Dr Clive Cornell, COO Simon Bury, Business Development Director – Discovery t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28:
CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30:
CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32:
CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34:
CONTACT Carina Schmidt Chief Execut
Page 35 and 36:
CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38:
CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89: CONTACT Dr Roman Schenk Chief Execu
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?